Kvartalsrapport Q3 2026

Fulltext

===== SIDA 1 =====

Press Release
26 June 2026 08:00:00 CEST
 Vivesto AB Box 3061 SE-169 03 Solna
Vivesto completes recruitment in Paccal Vet 
dog pilot study – topline results expected Q3 
2026
Solna, Sweden, June 26, 2026 – Vivesto AB, an oncology-focused development company, today 
announced the completion of recruitment in its clinical Paccal Vet pilot study in dogs with 
splenic hemangiosarcoma following splenectomy. Topline results from the study are expected 
during Q3 2026.
Eighteen evaluable dogs are now enrolled in the open label, exploratory pilot study evaluating 
Paccal Vet (paclitaxel micellar) in dogs with splenic hemangiosarcoma (HSA) following 
splenectomy. In the study, dogs with HSA are treated with up to 4 treatment cycles of Paccal Vet in 
intervals of 3 weeks across 8 clinical sites in the US. Overall survival and progression free survival 
is followed for up to 12 months.
“Completing recruitment marks an important execution milestone for the Paccal Vet program. We 
now look forward to the topline data at the end of this summer or early fall. The topline data will 
guide the next step in our ambition to bring a new treatment option for dogs diagnosed with this 
devastating and currently under-served cancer disease,” said Erik Kinnman, CEO of Vivesto. “The 
upcoming topline data will also be important in the ongoing partnering activities together with 
Liberi Group, in which discussions with leading players in the field are already underway."
In November 2025, Vivesto reported positive interim results from the study, indicating that 
treatment with Paccal Vet leads to longer overall survival in dogs with Stage I-II splenic 
hemangiosarcoma following splenectomy, compared with surgically treated historical controls.
Confirmation of the positive interim results would trigger initiation of a pivotal study to support full 
marketing approval for Paccal Vet in dogs with splenic hemangiosarcoma. Positive results may 
also open the path to conditional approval and early market entry ahead of pivotal study 
completion.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

===== SIDA 2 =====

Press Release
26 June 2026 08:00:00 CEST
 Vivesto AB Box 3061 SE-169 03 Solna
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-
treat cancers where there are major medical needs and significant market potential. The project 
portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary 
oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in 
dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats 
with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more 
information about Vivesto.
About Paccal Vet
Vivesto’s drug candidate Paccal Vet consists of paclitaxel formulated with the company’s 
proprietary XR-17 technology, which enables solubility without the undesirable effects of 
traditional formulations containing solvents. The absence of the solvent cremophor, to which cats 
and dogs are particularly sensitive, may reduce the risk of serious side effects and death 
associated with treatment.
Paccal Vet also does not require the addition of human albumin, which when used in cats and dogs 
can cause hypersensitivity reactions and reduced treatment effectiveness. Previous clinical studies 
performed by Vivesto have demonstrated safety in more than 300 dogs. Anti-tumor activity has 
also been shown in squamous cell carcinoma and non-resectable mammary carcinoma of stage III-
V. Vivesto is also conducting a Paccal Vet dose-finding study in cats with solid tumors.
About hemangiosarcoma in dogs
Hemangiosarcoma is one of the most common malignant cancers in dogs and is associated with a 
poor prognosis, with less than 10 percent of dogs surviving 12 months. The number of dogs 
diagnosed with hemangiosarcoma annually in the US and Europe is approximately 75,000 per 
market. Dogs with hemangiosarcoma rarely show clinical symptoms until the tumor has grown 
very large and spread. Hemangiosarcoma usually affects older dogs (>8 years) of all breeds. The 
tumor normally appears on the spleen, right heart base or liver, but can also be found on the skin 
and other sites such as the bones, kidneys, bladder, muscles, mouth and central nervous system.
Treatment options for hemangiosarcoma include surgery and, for some of the dogs, an unapproved 
adjuvant chemotherapy. The median survival time for dogs with hemangiosarcoma of the spleen 
undergoing surgery alone is approximately 1-3 months, depending on the stage/seriousness of the 
disease. No cancer medicines have been developed for the treatment of hemangiosarcoma in dogs. 
However, chemotherapeutic agents developed for human use are used off-label in dogs to manage 
residual metastatic disease after surgery. The most common such chemotherapy program in use 
today can extend survival with hemangiosarcoma of the spleen by 2-4 months.
Attachments
Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026